Elsevier

Biochemical Pharmacology

Volume 52, Issue 3, 9 August 1996, Pages 407-411
Biochemical Pharmacology

Research paper
Studies on the N-[(trans-4-Isopropylcyclohexyl)-carbonyl]-d-phenylalanine (A-4166) receptor in HIT T-15 cells: Displacement of [3H]glibenclamide

https://doi.org/10.1016/0006-2952(96)00242-0Get rights and content

Abstract

A-4166 is a new type of oral hypoglycemic agent that does not contain a sulfonylurea moiety. To clarify the mechanism of insulin secretion by A-4166, a specific receptor for A-4166 was investigated in a hamster pancreatic β cell line (HIT T-15), using [3H]A-4166 or [3H]glibenclamide as a ligand. The saturation binding of [3H]A-4166 to HIT cell membranes was not observed up to 10 μM. In the displacement study, unlabeled A-4166 inhibited [3H]A-4166 binding to HIT cell membranes, but glibenclamide did not. On the other hand, A-4166 inhibited [3H]glibenclamide binding to the sulfonylurea receptor (Ki = 248 nM). A-4166 inhibited 86Rb efflux from HIT cells (ic50 = 350 nM). The ec50 for insulin secretion by A-4166 was 20 μM in HIT cells when they were incubated for 30 min in Krebs-Ringer bicarbonate buffer containing 16 mM HEPES supplemented with 5 mg/mL BSA in the absence of glucose. These data demonstrate the possibility of the presence of two kinds of binding sites for A-4166: one of them is the sulfonylurea receptor, and the other might be a binding site specific for A-4166.

References (22)

  • H Hirose et al.

    Effects of d-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic α- and β-cells: Comparative study with glibenclamide

    Pharmacology

    (1995)
  • Cited by (23)

    View all citing articles on Scopus
    View full text